Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03100058 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

A Phase 2 study of Obesity and Overweight, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
460
Enrollment target
20
Study locations

NCT03100058 is a Phase 2 study of Obesity and Overweight that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 460 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03100058, a Phase 2 study of Obesity and Overweight, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
460 participants
Enrollment target
20
Study locations

Study Summary

This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo.

Conditions Studied

Obesity Overweight

Interventions

  • DRUG Placebo
  • DRUG LIK066

Study Locations (20)

California

  • Novartis Investigative Site - Beverly Hills
  • Novartis Investigative Site - Carmichael
  • Novartis Investigative Site - Concord
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Northridge
  • Novartis Investigative Site - Roseville
  • Novartis Investigative Site - San Ramon
  • Novartis Investigative Site - Stockton
  • Novartis Investigative Site - Walnut Creek

Florida

  • Novartis Investigative Site - Bradenton
  • Novartis Investigative Site - Fort Lauderdale
  • Novartis Investigative Site - Port Charlotte
  • Novartis Investigative Site - West Palm Beach

Alabama

  • Novartis Investigative Site - Anniston
  • Novartis Investigative Site - Jasper

Colorado

  • Novartis Investigative Site - Denver
  • Novartis Investigative Site - Golden

Georgia

  • Novartis Investigative Site - Athens
  • Novartis Investigative Site - Augusta

Hawaii

  • Novartis Investigative Site - Honolulu

Trial Details

FieldValue
Enrollment Target 460 participants
Start Date 2017-05-06
Est. Completion 2018-08-02
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03100058

The ClinicalTrials.gov registry entry for NCT03100058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (44% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03100058 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT03100058 about?

NCT03100058 is a clinical study titled "A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults". This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo.

What is the current status of trial NCT03100058?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 460 participants. The study started on 2017-05-06. Estimated completion is 2018-08-02.

What conditions does trial NCT03100058 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT03100058?

The interventions under investigation include: Placebo (DRUG), LIK066 (DRUG).

Who is sponsoring clinical trial NCT03100058?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03100058 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.